"No", I suppose. From the last paragraph: > For now, we remain on the cusp of a breakthrough that could neutralize our foe. A few months after my tour, BiondVa

"No", I suppose. From the last paragraph: > For now, we remain on the cusp of a breakthrough that could neutralize our foe. A few months after my tour, BiondVax announced the results of its Phase III trial. The researchers found that, in a randomized, double-blind test involving more than twelve thousand people, M-001 did not significantly reduce the incidence or severity of the flu. “For now, the M-001 vaccine candidate remains on the shelf, and we may return to it in the future,” Joshua Phillipson, the company’s director of business development and investor relations, told me.